Journal
ONCOTARGETS AND THERAPY
Volume 9, Issue -, Pages 5999-6008Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S109342
Keywords
colon cancer; tumor necrosis factor; alpha; chemotherapy; prognosis; tumor regression
Categories
Ask authors/readers for more resources
Colon cancer (CC) is among the most common malignant diseases with a dismal survival. Tumor necrosis factor-alpha (TNF-alpha) has been identified as a therapeutic target in various cancers, and anti-TNF-alpha treatment has shown promising effects in different cancer models. However, if TNF-alpha can be targeted in CC, the therapeutic values of anti-TNF-alpha treatment in CC remain unknown. Our study indicated that TNF-alpha is highly expressed in CC cell lines and patient tumor samples. High expression of TNF-alpha is an independent adverse prognosticator of CC. Targeting the TNF-alpha by its antibody infliximab induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and enhanced apoptosis leading to cell death. The combination of infliximab with 5-fluorouracil showed better responses in vitro and in vivo than 5-fluorouracil alone. In conclusion, this study identified TNF-alpha as a target of CC and anti-TNF-alpha treatment synergized with chemotherapy leading to a better outcome in preclinical models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available